MicroRNA-146a controls Th1-cell differentiation of human CD4+ T lymphocytes by targeting PRKCε

Patrick Möhnle1, Stefanie V Schütz, Verena van der Heide

  • 1Research Group Molecular Medicine, Department of Anesthesiology, University of Munich (LMU), Munich, Germany.

Insights

MicroRNA-146a (miR-146a) inhibits Th1-cell differentiation in human T cells by targeting protein kinase C epsilon (PRKCε). Reduced miR-146a and increased PRKCε are observed in sepsis patients.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cellular Biology

Background:

  • T-cell function requires strict regulation to balance inflammation and prevent overactivation.
  • MicroRNA-146a (miR-146a) is a known regulator of T-cell responses in mice.
  • The role of miR-146a in human T cells and inflammatory diseases is not well understood.

Purpose of the Study:

  • To investigate the function and molecular mechanisms of miR-146a in primary human T cells.
  • To determine the relevance of miR-146a dysregulation in human inflammatory conditions like sepsis.

Main Methods:

  • Characterization of miR-146a-driven pathways in human CD4(+) T cells.
  • Identification of miR-146a targets and their interacting partners.
  • Analysis of miR-146a and PRKCε levels in T cells from sepsis patients.

Main Results:

  • MiR-146a acts as a critical regulator of Th1-cell differentiation in human T cells.
  • MiR-146a directly targets protein kinase C epsilon (PRKCε).
  • PRKCε, in complex with STAT4, promotes Th1-cell differentiation.
  • Sepsis patients exhibit decreased miR-146a and increased PRKCε during the hyperinflammatory phase.

Conclusions:

  • MiR-146a is a potent inhibitor of Th1-cell differentiation in humans.
  • Dysregulation of miR-146a is implicated in the pathogenesis of sepsis.
  • The miR-146a/PRKCε/STAT4 pathway is a novel mechanism controlling human T-cell responses.